Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £73 | £78 | £51 | £46 |
| % Growth | -6.1% | 53.5% | 9.3% | – |
| Cost of Goods Sold | £42 | £43 | £33 | £29 |
| Gross Profit | £32 | £35 | £18 | £18 |
| % Margin | 43.2% | 44.5% | 35.3% | 38.3% |
| R&D Expenses | £35 | £29 | £16 | £28 |
| G&A Expenses | £0 | £15 | £13 | £13 |
| SG&A Expenses | £21 | £15 | £13 | £13 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | -£2 | £22 | £111 |
| Operating Expenses | £56 | £42 | £50 | £151 |
| Operating Income | -£24 | -£9 | -£32 | -£132 |
| % Margin | -33% | -12.1% | -63.5% | -283% |
| Other Income/Exp. Net | -£2 | -£2 | -£3 | -£5 |
| Pre-Tax Income | -£26 | -£12 | -£36 | -£136 |
| Tax Expense | £1 | £1 | £1 | -£5 |
| Net Income | -£26 | -£11 | -£32 | -£110 |
| % Margin | -36% | -13.7% | -63.9% | -235.7% |
| EPS | -0.25 | -0.1 | -0.31 | -1.13 |
| % Growth | -150% | 67.7% | 72.6% | – |
| EPS Diluted | -0.25 | -0.1 | -0.31 | -1.13 |
| Weighted Avg Shares Out | 106 | 106 | 105 | 97 |
| Weighted Avg Shares Out Dil | 106 | 106 | 105 | 97 |
| Supplemental Information | – | – | – | – |
| Interest Income | £1 | £1 | £2 | £3 |
| Interest Expense | £7 | £5 | £5 | £4 |
| Depreciation & Amortization | £13 | £11 | £11 | £14 |
| EBITDA | -£6 | £5 | -£20 | -£112 |
| % Margin | -8.3% | 6.4% | -38.7% | -241.5% |